HomeCompareALIM vs O

ALIM vs O: Dividend Comparison 2026

ALIM yields 36.10% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ALIM wins by $152.8K in total portfolio value
10 years
ALIM
ALIM
● Live price
36.10%
Share price
$5.54
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$187.1K
Annual income
$29,005.40
Full ALIM calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — ALIM vs O

📍 ALIM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALIMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALIM + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALIM pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALIM
Annual income on $10K today (after 15% tax)
$3,068.59/yr
After 10yr DRIP, annual income (after tax)
$24,654.59/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, ALIM beats the other by $20,317.26/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALIM + O for your $10,000?

ALIM: 50%O: 50%
100% O50/50100% ALIM
Portfolio after 10yr
$110.6K
Annual income
$17,054.07/yr
Blended yield
15.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

ALIM
Analyst Ratings
9
Buy
4
Hold
Consensus: Buy
Price Target
$5.75
+3.8% upside vs current
Range: $5.50 — $6.00
Altman Z
-1.4
Piotroski
1/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALIM buys
0
O buys
0
No recent congressional trades found for ALIM or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALIMO
Forward yield36.10%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$187.1K$34.2K
Annual income after 10y$29,005.40$5,102.74
Total dividends collected$136.3K$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyHold
Analyst price target$5.75$64.00

Year-by-year: ALIM vs O ($10,000, DRIP)

YearALIM PortfolioALIM Income/yrO PortfolioO Income/yrGap
1← crossover$14,310$3,610.11$10,818$608.16+$3.5KALIM
2$20,140$4,828.13$11,787$741.68+$8.4KALIM
3$27,900$6,350.55$12,946$911.00+$15.0KALIM
4$38,075$8,222.00$14,345$1,127.94+$23.7KALIM
5$51,227$10,486.45$16,056$1,409.05+$35.2KALIM
6$67,999$13,185.62$18,171$1,777.83+$49.8KALIM
7$89,116$16,357.51$20,820$2,268.21+$68.3KALIM
8$115,389$20,035.00$24,188$2,929.90+$91.2KALIM
9$147,711$24,244.58$28,533$3,837.11+$119.2KALIM
10$187,056$29,005.40$34,235$5,102.74+$152.8KALIM

ALIM vs O: Complete Analysis 2026

ALIMStock

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Full ALIM Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this ALIM vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALIM vs SCHDALIM vs JEPIALIM vs KOALIM vs MAINALIM vs STAGALIM vs ADCALIM vs NNNALIM vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.